Spots Global Cancer Trial Database for hairy cell leukemia
Every month we try and update this database with for hairy cell leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Therapy Optimisation for the Treatment of Hairy Cell Leukemia | NCT02131753 | Hairy Cell Leuk... | Cladribine s.c.... | 18 Years - 90 Years | University of Giessen | |
| Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | NCT00924040 | Hairy Cell Leuk... | BL22 (CAT-3888) | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Assessment of the V600E Mutation in the B-RAF Gene in Chronic Lymphoproliferative Disease | NCT01720758 | Hairy Cell Leuk... Splenic Margina... | 18 Years - | HaEmek Medical Center, Israel | ||
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | NCT05645744 | Blastic Plasmac... Chronic Lymphoc... Small Lymphocyt... Waldenstrom's M... Follicular B-ce... B-cell Lymphoma... Mantle Cell Lym... Hairy Cell Leuk... Diffuse Large B... Waldenstrom's M... Mantle Cell Lym... | Prior MB-102 CA... Prior MB-106 CA... | 18 Years - | Mustang Bio | |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | NCT05388123 | Hairy Cell Leuk... | Low dose vemura... | 18 Years - 90 Years | Scripps Health | |
| Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant | NCT04815356 | Hairy Cell Leuk... Hairy Cell Leuk... | CD22CART cell i... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | NCT01059786 | Hairy Cell Leuk... | Pentostatin Rituximab Bendamustine Acetaminophen Diphenhydramine Epinephrine Antihistamines Corticosteroids Bronchodilators Intravenous (IV... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| 17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Systemic Mastocytosis | NCT00132015 | Chronic Myelopr... Leukemia Lymphoma Nonneoplastic C... Precancerous Co... | tanespimycin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant | NCT04322383 | Hairy Cell Leuk... | binimetinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Ibrutinib in Treating Patients With Relapsed Hairy Cell Leukemia | NCT01841723 | Hairy Cell Leuk... Hairy Cell Leuk... Recurrent Hairy... | Ibrutinib | 18 Years - | National Cancer Institute (NCI) | |
| Assessing Medical Trial Experiences of Hairy Cell Leukemia Patients | NCT05859932 | Hairy Cell Leuk... | 18 Years - | Power Life Sciences Inc. | ||
| Cladribine and Rituximab in Treating Patients With Hairy Cell Leukemia | NCT00412594 | Hairy Cell Leuk... Recurrent Hairy... | Cladribine Laboratory Biom... Rituximab | 18 Years - | M.D. Anderson Cancer Center | |
| Retreatment Protocol for BL22 Immunotherapy in Relapsed or Refractory Hairy Cell Leukemia | NCT00924040 | Hairy Cell Leuk... | BL22 (CAT-3888) | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| US Post-Marketing Safety Study of Moxetumomab Pasudotox-tdfk (LUMOXITI) | NCT04125290 | Hairy Cell Leuk... | - | AstraZeneca | ||
| A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | NCT00001567 | Hairy Cell Leuk... | Roferon-A | - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | NCT03010358 | Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom... | Entospletinib Laboratory Biom... Obinutuzumab Pharmacological... | 18 Years - | OHSU Knight Cancer Institute | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Moxetumomab Pasudotox-tdfk (Lumoxiti(TM)) and Either Rituximab (Rituxan(R)) or Ruxience for Relapsed Hairy Cell Leukemia | NCT03805932 | Hairy Cell Leuk... | Moxetumomab Pas... Rituximab Ruxience Dexamethasone Acetaminophen Diphenhydramine Famotidine Aspirin | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Encorafenib Plus Binimetinib for People With BRAF V600 Mutated Relapsed/Refractory HCL | NCT04324112 | Hairy Cell Leuk... | binimetinib Encorafenib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | NCT00001567 | Hairy Cell Leuk... | Roferon-A | - | National Institutes of Health Clinical Center (CC) | |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas | NCT06340737 | Follicular Lymp... Mantle Cell Lym... Hairy Cell Leuk... Lymphoplasmacyt... Burkitt Lymphom... Marginal Zone L... Waldenstrom Mac... | CD22CART Infusi... | 18 Years - | Stanford University | |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | NCT00923013 | Hairy Cell Leuk... | Cladribine Rituximab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Collecting and Storing Malignant, Borderline Malignant Neoplasms, and Related Samples From Young Patients With Cancer | NCT00898079 | Acute Undiffere... Atypical Chroni... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Solid... Chronic Lymphoc... Hairy Cell Leuk... Juvenile Myelom... Mast Cell Leuke... Neoplasm of Unc... Prolymphocytic ... Secondary Acute... T-Cell Large Gr... | Cytology Specim... | - 30 Years | Children's Oncology Group | |
| Randomized Phase II Trial of Rituximab With Either Pentostatin or Bendamustine for Multiply Relapsed or Refractory Hairy Cell Leukemia | NCT01059786 | Hairy Cell Leuk... | Pentostatin Rituximab Bendamustine Acetaminophen Diphenhydramine Epinephrine Antihistamines Corticosteroids Bronchodilators Intravenous (IV... | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product. | NCT05645744 | Blastic Plasmac... Chronic Lymphoc... Small Lymphocyt... Waldenstrom's M... Follicular B-ce... B-cell Lymphoma... Mantle Cell Lym... Hairy Cell Leuk... Diffuse Large B... Waldenstrom's M... Mantle Cell Lym... | Prior MB-102 CA... Prior MB-106 CA... | 18 Years - | Mustang Bio | |
| BRAF Inhibitor, Vemurafenib, in Patients With Relapsed or Refractory Hairy Cell Leukemia | NCT01711632 | Hairy Cell Leuk... | Vemurafenib | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Low Dose Vemurafenib and Rituximab in Hairy Cell Leukemia | NCT05388123 | Hairy Cell Leuk... | Low dose vemura... | 18 Years - 90 Years | Scripps Health | |
| A Phase II Efficacy Study of Roferon-A in Hairy Cell Leukemia | NCT00001567 | Hairy Cell Leuk... | Roferon-A | - | National Institutes of Health Clinical Center (CC) | |
| Phase I/IIa Study to Evaluate the Safety, PK, PD, and Preliminary Efficacy of PLX8394 in Patients With Advanced Cancers. | NCT02012231 | Melanoma Thyroid Cancer Colorectal Canc... Non-small Cell ... Cholangiocarcin... Histiocytosis Hairy Cell Leuk... | PLX8394 | 18 Years - | Fore Biotherapeutics | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Cladribine With Simultaneous or Delayed Rituximab to Treat Hairy Cell Leukemia | NCT00923013 | Hairy Cell Leuk... | Cladribine Rituximab | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic Malignancies | NCT02362035 | Follicular Lymp... CLL Small Lymphocyt... Richter's Syndr... Mantle Cell Lym... Indolent Non Ho... Waldenström Mac... Multiple Myelom... Hodgkin Lymphom... Burkitt Lymphom... Marginal Zone L... Mediastinal Lar... Hairy Cell Leuk... | Acalabrutinib Pembrolizumab | 18 Years - | Acerta Pharma BV | |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189 | Leukemia Hairy Cell Leuk... HCL | Immunotoxin the... CAT-8015 Immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology | |
| Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma | NCT03010358 | Anemia B-Cell Prolymph... Grade 1 Follicu... Grade 2 Follicu... Grade 3a Follic... Hairy Cell Leuk... Lymphoplasmacyt... Mantle Cell Lym... Marginal Zone L... Recurrent Chron... Recurrent Small... Refractory Chro... Refractory Smal... Richter Syndrom... | Entospletinib Laboratory Biom... Obinutuzumab Pharmacological... | 18 Years - | OHSU Knight Cancer Institute | |
| A Phase II Study of the BRAF Inhibitor, Vemurafenib, Plus Obinutuzumab in Patients With Previously Untreated Classical Hairy Cell Leukemia | NCT03410875 | Hairy Cell Leuk... Leukemia Leukemia, Hairy... | Vemurafenib Obinutuzumab | 18 Years - | Memorial Sloan Kettering Cancer Center | |
| Safety Study of CAT-8015 Immunooxin in Patients With HCL With Advance Disease | NCT00462189 | Leukemia Hairy Cell Leuk... HCL | Immunotoxin the... CAT-8015 Immuno... Biological ther... | 18 Years - | Cambridge Antibody Technology |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
